Concepts
MDMA-Assisted Therapy
Summary
MDMA-assisted therapy is a treatment model combining MDMA administration with structured psychotherapy for PTSD. Typically 2-3 sessions of 8 hours each. Developed primarily by MAPS…
Research notes
Context, reporting, and structured background for this dossier.
MDMA-assisted therapy is a treatment model combining MDMA administration with structured psychotherapy for PTSD. Typically 2-3 sessions of 8 hours each. Developed primarily by MAPS over 30+ years. Rejected by the FDA in August 2024.
Related entities
Other dossiers that help connect this page to the wider reporting record.
- MDMA
MDMA (3,4-methylenedioxymethamphetamine) is an entactogen under investigation for PTSD treatment. Lykos Therapeutics' application for FDA approval was rejected in August 2024. Rela…
- Lykos Therapeutics
Lykos Therapeutics is the commercial entity that took over the MDMA-assisted therapy for PTSD approval path from MAPS and remains the focal company in the FDA midomafetamine saga.
- MAPS (Multidisciplinary Association for Psychedelic Studies)
MAPS is the nonprofit organization that incubated and sponsored the modern MDMA-assisted therapy for PTSD program before the commercial approval effort moved into Lykos Therapeutics.
- FDA
The U.S. Food and Drug Administration is the gatekeeper for psychedelic drug development in the United States, from IND clearance through advisory committee review and any eventual approval or rejection.